Sign up Australia
Proactive Investors - Run By Investors For Investors
Why invest in CYP?
Cynata Therapeutics: THE INVESTMENT CASE

Cynata Therapeutics: Access latest PPT from Proactive's CEO Sessions

Dr Ross Macdonald talked stemcell research with investors.
Cynata Therapeutics: Access latest PPT from Proactive's CEO Sessions
INVESTMENT OVERVIEW: CYP The Big Picture
Dr Ross Macdonald, CEO, Cynata Therapeutics

Cynata Therapeutics' (ASX:CYP) CEO, Dr Ross Macdonald, joined Proactive's CEO Sessions in Sydney on Tuesday 14th March and Melbourne on Wednesday 15th March.

Cynata is now in a transition to a clinical stage company, with the focus on stem cells and regenerative medicine.

Earlier this year Cynata announced a breakthrough strategic partnership with Fujifilm which included the Japanese company investing in the company to become the largest shareholder.

 

ACCESS THE FULL PRESENTATION HERE



Register here to be notified of future CYP Company articles
View full CYP profile

Cynata Therapeutics Timeline

Newswire
January 19 2017

Related Articles

picture of pregnant woman
February 07 2017
MyLotus has been developed for women who have been trying to conceive for six months or more.
shutterstock_127456451.jpg
March 30 2017
PIFA Heparin PF/4 - a diagnostic test for allergic reactions to blood thinning agent Heparin - achieved an 85% jump in sales in 2016
Genetic data
July 12 2016
Drug discovery company snaps up software system for "non-material" sum

© Proactive Investors 2017

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use